Brokers Issue Forecasts for Sight Sciences Q1 Earnings

Key Points

• HC Wainwright forecasts Sight Sciences will post a Q1 2027 loss of $0.09 per share and maintains a Buy rating with a $14 price target.
• Analyst sentiment is broadly positive: the stock has a consensus “Moderate Buy” rating and an average price target of $9.62, with eight analysts covering it.
• In its latest quarter, Sight Sciences reported a $0.12-per-share loss, in line with estimates, while revenue of $24.92 million topped forecasts of $23.55 million.

Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Sight Sciences in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of ($0.09) for the quarter. HC Wainwright has a "Buy" rating and a $14.00 price target on the stock. The consensus estimate for Sight Sciences' current full-year earnings is ($0.48) per share.

Other equities analysts have also issued research reports about the company. UBS Group raised their target price on Sight Sciences from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Piper Sandler reiterated an "overweight" rating and set a $12.00 price target (up from $9.00) on shares of Sight Sciences in a research note on Thursday. Wall Street Zen upgraded Sight Sciences from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Citigroup increased their price objective on Sight Sciences from $8.00 to $10.00 and gave the company a "neutral" rating in a report on Monday, October 5th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Sight Sciences in a research note on Wednesday. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $9.62.

Sight Sciences Trading Up 0.8%

NASDAQ:SGHT opened at $9.76 on Friday. The company has a market capitalization of $537.66 million, a P/E ratio of -18.77 and a beta of 2.44. The company has a current ratio of 4.95, a quick ratio of 4.67 and a debt-to-equity ratio of 0.58. Sight Sciences has a 12 month low of $3.38 and a 12 month high of $10.31. The firm has a fifty day simple moving average of $8.68 and a 200-day simple moving average of $6.07.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.12). The business had revenue of $24.92 million for the quarter, compared to analyst estimates of $23.55 million. Sight Sciences had a negative net margin of 32.13% and a negative return on equity of 42.41%.

Hedge Funds Weigh In On Sight Sciences

Institutional investors have recently modified their holdings of the stock. R Squared Ltd raised its position in Sight Sciences by 20.7% during the third quarter. R Squared Ltd now owns 19,759 shares of the company's stock valued at $185,000 after acquiring an additional 3,388 shares in the last quarter. Hsbc Holdings PLC boosted its position in Sight Sciences by 21.6% in the 2nd quarter. Hsbc Holdings PLC now owns 46,707 shares of the company's stock worth $255,000 after purchasing an additional 8,297 shares in the last quarter. Bank of America Corp DE purchased a new stake in Sight Sciences in the 2nd quarter worth approximately $520,000. Canada Pension Plan Investment Board purchased a new stake in Sight Sciences in the 2nd quarter worth approximately $299,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Sight Sciences during the 2nd quarter worth approximately $60,000. Hedge funds and other institutional investors own 55.51% of the company's stock.

Insider Buying and Selling at Sight Sciences

In other news, CTO David Badawi sold 7,797 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $9.05, for a total value of $70,562.85. Following the sale, the chief technology officer owned 1,975,075 shares in the company, valued at $17,874,428.75. This represents a 0.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Paul Badawi sold 29,653 shares of the firm's stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $9.05, for a total transaction of $268,359.65. Following the transaction, the chief executive officer directly owned 6,092,819 shares of the company's stock, valued at approximately $55,140,011.95. This trade represents a 0.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 47,646 shares of company stock valued at $429,157 over the last quarter. Insiders own 30.40% of the company's stock.

Key Headlines Impacting Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Higher 2026 outlook: Sight Sciences raised its full-year revenue guidance to $92–$93 million and indicated a higher 2026 revenue target for its iDose product. The improved outlook may support expectations for continued growth. Article: Sight Sciences signals 2026 revenue outlook
• Positive Sentiment: CMS reimbursement development: CMS established a direct practice-expense supply code for TearCare SmartLids, a single-use component of the TearCare system. This could help clarify reimbursement and support adoption. Article: CMS establishes a TearCare SmartLids supply code
• Positive Sentiment: Revenue beat and analyst support: Third-quarter revenue was $24.92 million, above analysts’ $23.55 million estimate. Piper Sandler reaffirmed its Overweight rating and raised its price target to $12 from $9, signaling confidence in further upside. Analyst rating information
• Neutral Sentiment: Losses persist, but met expectations: SGHT reported a third-quarter loss of $0.12 per share, in line with consensus and narrower than the $0.16 loss a year earlier. The company remains unprofitable, which may temper the positive growth news. Article: Sight Sciences reports Q3 loss and revenue beat

Sight Sciences Company Profile

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company's portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye's natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.